Clinical Trials

160 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

182 enrolled

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07331155 2026-05-18

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

110 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT07136077 2026-05-15

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

20 enrolled

Colorectal Neoplasms, Neoplasm, Residual

NCT07390383 2026-05-13

A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]

110 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT07413354 2026-05-12

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Carcinoma, Hepatocellular

NCT07554521 2026-05-11

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

Esophageal Squamous Cell Carcinoma

NCT07019675 2026-05-08

A Study of SKB518 in Patients With Lung Cancer

192 enrolled

Lung Neoplasms

NCT07040956 2026-05-04

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

98 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

38 enrolled

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT07561983 2026-05-01

BEACON-Lung

39 enrolled

Unresectable Stage III Non-small Cell Lung Cancer

NCT07557914 2026-04-30

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes - A Multicenter, Prospective, Single-arm Clinical Study

32 enrolled

Diabetes Mellitus, Carcinoma, Hepatocellular

NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Phase 2 Terminated

40 enrolled

Extensive Stage Small Cell Lung Cancer

NCT06536868 2026-04-24

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

40 enrolled

Small Cell Lung Carcinoma

NCT03736889 2026-04-22

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

200 enrolled

Other solid neoplasm

MSI-H/dMMR Solid Tumors

NCT05519865 2026-04-20

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

118 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06233981 2026-04-17

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

Carcinoma, Hepatocellular

NCT05635708 2026-04-15

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07528274 2026-04-14

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07518706 2026-04-09

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

60 enrolled

Carcinoma, Hepatocellular

NCT07512674 2026-04-06

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis

NCT07469306 2026-03-13

Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

130 enrolled

Locally Advanced Rectal Cancer

NCT07120282 2026-03-09

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

108 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05502250 2026-03-06

HOVON164HL

75 enrolled

Lymphoid

Hodgkin Disease

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07432984 2026-02-25

FMT-LUNG

15 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06356597 2026-02-24

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Colorectal Neoplasms

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Lymphoid

Lymphoma, Follicular

NCT05116085 2026-02-13

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

33 enrolled 11 charts

Colorectal Neoplasms

NCT05577702 2026-02-09

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

121 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

37 enrolled

Nasopharyngeal Carcinoma

NCT07370337 2026-01-27

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

50 enrolled

Squamous Cell Carcinoma of External Auditory Canal

NCT07363512 2026-01-23

Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus

27 enrolled

Carcinoma, Hepatocellular

NCT05254847 2026-01-20

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

65 enrolled

Biliary Tract Neoplasms

NCT05366829 2026-01-20

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

35 enrolled

Carcinoma, Hepatocellular

NCT07346807 2026-01-16

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

69 enrolled

Tongue Squamous Cell Carcinoma

NCT07330037 2026-01-09

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

41 enrolled

NSCLC

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

25 enrolled

Nasopharyngeal Carcinoma

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05532319 2025-12-30

FRONT-1

64 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07304258 2025-12-26

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

Gastric Cancer Peritoneal Metastases

NCT06722183 2025-12-24

FUTURE

Colorectal Neoplasms

NCT07296705 2025-12-22

HARBOR

25 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT05977673 2025-12-08

FIL_Tisle-HL

28 enrolled

Lymphoid

Hodgkin Disease, Lymphoma

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

32 enrolled

Genitourinary

Prostatic Neoplasms

NCT07264647 2025-12-04

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn